114676-67-4

Basic information

• Product Name: (2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine
• Synonyms: (2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine;4-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxymethyl-pyrrolidine-1-carboxylic acid;(2S,4R)-tert-Butyl 4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS NO: 114676-67-4
• Molecular Formula: C₁₆H₃₃NO₄Si
• Molecular Weight: 331.52302
• Mol File: 114676-67-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine(114676-67-4)
• EPA Substance Registry System: (2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine(114676-67-4)

Safety Data

• Hazardous Substances Data: 114676-67-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine is used as a building block for the construction of complex molecules and natural products. Its Boc protecting group allows for mild acidic deprotection, enabling further manipulation of the molecule in organic synthesis.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine is used as a key intermediate in the synthesis of various drug candidates. The tert-butyldimethylsilyloxy group provides stability to the alcohol functionality during chemical reactions, facilitating the development of new therapeutic agents.
Used in Chemical Research:
(2S,4R)-1-Boc-4-(tert-butyldiMethylsilyloxy)-2-(hydroxyMethyl)pyrrolidine is also utilized in chemical research for studying the reactivity and selectivity of various functional groups. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic methods.

Upstream product

• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 117811-66-2 (2S,4R)-4-t-butyldimethylsilyloxy-2-hydroxymethylpyrrolidine 
• 104795-11-1 (2S,4R)-1-benzyloxycarbonyl-4-<(tert-butyldimethylsilyl)oxy>-2-(hydroxymethyl)pyrrolidine 
• 151953-64-9 (3R,5S)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}pyrrolidine-3-ol 
• 753014-18-5 1-tert-butyl 2-ethyl (2S,4R)-4-{[tert-butyl (dimethyl)silyl]oxy} pyrrolidine-1,2-dicarboxylate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 51-35-4 4R-4-hydroxyproline 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 114676-91-4 1-tert-butyl 2-methyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}pyrrolidine-1,2-dicarboxylate 
• 1159609-88-7 N-t-butoxycarbonyl-4-(R)-t-butyldimethylsilyloxy proline methyl ester 
• 7757-82-6 sodium sulfate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 1194059-65-8 tert-butyl (2S,4R)-4-(tert-butyl(dimethyl)silyl)oxy-2-{1-((phenoxycarbonothioyl)oxy)-3-(trimethyl-silyl)prop-2-yn-1-yl}pyrrolidine-1-carboxylate 
• 857651-10-6 tert-butyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-({[(4-methylphenyl)-sulfonyl]-oxy}methyl)pyrrolidine-1-carboxylate 
• 136024-65-2 (2-Amino-3-hydroxy-phenyl)-((2S,4R)-2-diethoxymethyl-4-hydroxy-pyrrolidin-1-yl)-methanone 
• 114676-93-6 (2R,4R)-tert-butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate 
• 859213-36-8 (2R,4R)-tert-butyl 2-methyl-4-(tosyloxy)pyrrolidine-1-carboxylate 
• 348165-62-8 (2R,4S)-tert-butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate 
• 1257235-37-2 (1-{1-[4-benzylcarbamoyl-6-(4-fluoro-benzyloxy)-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-ethyl)-methyl-carbamic acid benzyl ester 
• 1257235-00-9 (1-{1-[6-(3,4-difluoro-phenoxy)-4-(tetrahydro-pyran-4-yl)-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-ethyl)-methyl-carbamic acid benzyl ester 
• 1257235-51-0 {1-[1-(6-benzylcarbamoyloxy-4-isopropylcarbamoyl-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl)-2,2-dimethyl-propylcarbamoyl]-ethyl}-methyl-carbamic acid benzyl ester 
• 1257235-12-3 4-{2-[2-(benzyloxycarbonyl-methyl-amino)-propionylamino]-3,3-dimethyl-butyryl}-3-(3,4-difluoro-phenoxy)-hexahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid tert-butyl ester 
• 1257235-08-7 (1-{1-[6-(3,4-difluoro-phenoxy)-4-(tetrahydro-pyran-4-yl)-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-ethyl)-methyl-carbamic acid benzyl ester 
• 1257235-20-3 (1-{1-[6-(3,4-difluoro-phenoxy)-4-methylcarbamoyl-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-ethyl)-methyl-carbamic acid benzyl ester 
• 1257235-33-8 4-{2-[2-(benzyloxycarbonyl-methyl-amino)-propionylamino]-3,3-dimethyl-butyryl}-3-(4-fluoro-benzyloxy)-hexahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid tert-butyl ester 
• 1257235-16-7 (1-{1-[6-(3,4-difluoro-phenoxy)-4-methanesulfonyl-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-ethyl)-methyl-carbamic acid benzyl ester 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.

Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis

A series of 7H-pyrrolo[2,3-d]pyrimidine derivatives were designed and synthesized as reversible BTK inhibitors, and evaluated their kinase selectivity, anti-proliferation against the B-cell lymphoma cell lines (Ramos, Jeko-1) and cell line BTK enhanced (Daudi) in vitro. Among them, compound 28a exhibited the most excellent potency (IC50 = 3.0 nM against BTK enzyme, 8.52 μM, 11.10 μM and 7.04 μM against Ramos, Jeko-1, Daudi cells, respectively), good kinase selectivity and inhibited BTK Y223 auto-phosphorylation and PLCγ2 Tyr1217 phosphorylation. Importantly, 28a showed efficacy anti-arthritic effect on collagen-induced arthritis (CIA) model in vivo. 28a 60 mg/kg dose level once a day group displayed markedly reduced joint damage and cellular infiltration without any bone and cartilage morphology change.

PYRIDAZINONES AS PARP7 INHIBITORS

The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.

MULTI-TARGETED SINGLE ENTITY CONJUGATES

The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.

Amino 6-membered ring derivative and pharmaceutical applications thereof including the use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor

The present invention relates to an amino 6-membered ring derivative and pharmaceutical applications thereof, which specifically relates to the amino 6-membered ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, a prodrug, a pharmaceutical composition comprising the derivative, and the pharmaceutical use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as described in the specification.

4-Fluoro and 4-hydroxy pyrrolidine-thioxotetrahydropyrimidinones: Organocatalysts for green asymmetric transformations in brine

The synthesis of both trans- and cis-diastereomers of pyrrolidinine-thioxotetrahydropyrimidinone bearing either a fluorine or a hydroxyl group was accomplished. The new compounds were tested for their catalytic properties in a variety of asymmetric organic transformations and compared with the first generation catalyst. It was found that the new catalysts could efficiently catalyze the reactions in brine, without the use of organic solvent, and by employing an almost stoichiometric amount of reagents. Thus, the products were isolated by simple extractions, avoiding the use of chromatography in excellent yields, diastereoselectivities, and enantioselectivities.

BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1 , R2, R3 and R4 are as defined herein.

An Efficient approach to the securinega alkaloids empowered by cooperative n-heterocyclic carbene/lewis acid catalysis

Folding it all together: Most of the syntheses developed for the securinega alkaloid class require lengthy sequences to create their bridging butenolide domains. A novel approach uses N-heterocyclic carbenes (NHCs) and Lewis acids to forge the entire domain in a single step from appropriate precursors, showing that ynal-derived homoenolates can participate as nucleophiles in intramolecular settings (see scheme). Copyright

A novel method to access chiral nonnatural 2,4-disubstituted pyrrolidines from aldehydes and nitroolefins only with an α-substituent

A series of α-substituted nitroolefins were employed in organocatalytic asymmetric Michael reactions with aldehydes. γ-Nitro carbonyl products were achieved in good yields (up to 86%) with good stereoselectivities (up to 96% ee and 24 : 1 dr). Reduction of the nitro group followed by intramolecular reductive amination successfully afforded various novel optically active 2,4-disubstituted pyrrolidine compounds.

Design, synthesis, and antileukemic activity of stereochemically defined constrained analogues of FTY720 (Gilenya)

FTY720 functions as an immunosuppressant due to its effect on sphingosine-1-phosphate receptors. At doses well above those needed for immunosuppression, FTY720 also has antineoplastic actions. Our published work suggests that at least some of FTY720's anticancer activity is independent of its effects on S1P receptors and due instead to its ability to induce nutrient transporter down-regulation. Compounds that trigger nutrient transporter loss but lack FTY720's S1P receptor-related, dose-limiting toxicity have the potential to be effective and selective antitumor agents. In this study, a series of enantiomerically pure and stereochemically diverse O-substituted benzyl ethers of pyrrolidines was generated and tested for the ability to kill human leukemia cells. The stereochemistry of the hydroxymethyl was found to be a key determinant of compound activity. Moreover, phosphorylation of this group was not required for antileukemic activity.